search for




 

Socioeconomic Costs of Age-related Macular Degeneration in Korea
한국인 연령관련황반변성환자의 사회적 비용 분석
JKOS 2019 Aug;60(8):765-72
Published online August 15, 2019;  https://doi.org/10.3341/jkos.2019.60.8.765
Copyright © 2019 The Korean Ophthalmological Society.
PDF Download Count: 108 / View Count: 80

Yongsun Ahn, MD1,2, Donghyun Jee, MD, PhD, MPH1
안용선1,2 · 지동현1

Department of Ophthalmology, College of Medicine, The Catholic University of Korea1, Seoul, Korea
Suncheon Public Health Center2, Suncheon, Korea
가톨릭대학교 의과대학 안과학교실1, 순천시 보건소2
Received June 21, 2018; Revised September 19, 2018; Accepted July 18, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Purpose: To estimate the annual socioeconomic costs of age-related macular degeneration (AMD) in the Republic of Korea.
Methods: We estimated the costs of illness to society of AMD patients, including medical, nonmedical, and productivity costs. The medical costs included official and nonofficial medical costs, and the nonmedical costs consisted of transportation, time, and nursing costs. We used Korea National Health Insurance Claims Database, National Health Insurance Service-National Sample Cohort, and Korea Health Panel study data in the analysis.
Results: The socioeconomic costs of AMD were estimated to be 694 billion Korean won (KRW) in 2016. This figure was divided into 501 billion KRW (72.1%) for medical costs, 61 billion KRW (8.8%) for nonmedical costs, and 133 billion KRW (19.1%) for productivity costs. The annual per capita socioeconomic cost of AMD was 1.32 million KRW.
Conclusions: We determined the scale and composition of the socioeconomic costs of AMD. Importantly, the productivity costs accounted for approximately 20% of all costs, suggesting that AMD had a significant impact on productivity. Because the disease costs of AMD are expected to increase continuously with the aging population, effective planning at the governmental level for prevention and treatment of AMD should be considered to reduce socioeconomic costs.
Keywords : Age-related macular degeneration, Costs, Disease costs, Socioeconomic costs

 

September 2019, 60 (9)